Regeneron's core Eylea patent position is strengthened after the court dismissed several high-impact claims from Amgen. However, the laches counterclaim survives, meaning a path to unenforceability of the '099 patent remains open. Monitor developments on laches and whether Amgen seeks leave to amend its antitrust claims on the 2024 Litigation Patents. Next major catalyst is likely the claim construction or summary judgment rulings on the '099 patent's validity.
Drug in focus
REGN drug pipeline →EYLEA HD
● Neutral Named in this court ruling- Impact
- Phase
- Approved
- Time to market
- Already approved and on the market (since August 2023)
- Next catalyst
- None dated
What to watchEYLEA HD is a mature commercial asset, watch quarterly sales trends as a pulse check on how well Regeneron is defending share against Roche's Vabysmo and upcoming biosimilars (Samsung Bioepis Opuviz eligible Jan 2027). The real binary catalyst for REGN in the next 12 months is garetosmab's PDUFA in August 2026 for FOP. EYLEA HD's contribution is a gradual commercial story, not a binary event.
- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● Libtayo 4/10 Approved
- 11 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 8 $662.88entry
- T+1 · 4mo ago +0.76%α −0.08% · $667.95
- T+5 · 4mo ago +0.24%α −1.03% · $664.45
- T+20 · 3mo ago +15.95%α +12.67% · $768.58
- T+60 · 7w ago +10.85%α +8.36% · $734.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron won a significant motion in its patent infringement litigation against Amgen, with the court striking Amgen's inequitable conduct, patent misuse, and unclean hands defenses and dismissing related counterclaims with prejudice, and dismissing antitrust/UCL counterclaims with prejudice as to the '099 patent. The laches defense and counterclaim survive, preserving some uncertainty, but the ruling substantially narrows the case and removes high-risk claims that could have threatened enforceability of Regeneron's Eylea patents.
Court Ruling Details
Key Facts
- Court struck Amgen's inequitable conduct defense/counterclaim with prejudice (Thirteenth Additional Defense and Fourth Counterclaim)
- Court struck Amgen's patent misuse defense/counterclaim with prejudice (Fourteenth Additional Defense and Fifth Counterclaim)
- Court struck Amgen's unclean hands defense with prejudice (Fourth Additional Defense)
- Court dismissed Amgen's antitrust counterclaims with prejudice as to the '099 patent and without prejudice as to the 2024 Litigation Patents
- Court dismissed Amgen's UCL counterclaim with prejudice as to the '099 patent and without prejudice as to the 2024 Litigation Patents
- Court denied Regeneron's motion to dismiss Amgen's laches defense and counterclaim, allowing that claim to proceed
- The ruling does not address the validity or infringement of the '099 patent itself; no damages were awarded
Financial Impact
No damages awarded. The ruling removes the risk of the '099 patent being found unenforceable due to inequitable conduct, patent misuse, or unclean hands, and eliminates antitrust exposure tied to the '099 patent. The laches claim survival keeps some risk of unenforceability alive.
Risk Factors
- The laches defense and counterclaim survive, potentially creating a path to unenforceability of the '099 patent
- Antitrust counterclaims related to the 2024 Litigation Patents were dismissed without prejudice and could be repleaded
- The underlying patent infringement case continues, and Regeneron lost its preliminary injunction bid earlier
- Post-trial or appeal could reverse favorable rulings on inequitable conduct or patent misuse
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-d2d7cbf308-REGN |
Track record
53 reports on REGN
10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers